NEMODNaval European Meteorology and Oceanography Detachment
References in periodicals archive ?
BERLIN -- BERLIN, June 17 /PRNewswire/ -- NEMOD Immuntherapie AG, a drug discovery company focusing on oncological indications, today presented promising preclinical biodistribution data for the systemic delivery of the company's proprietary PankoMab(TM) antibody targeting the TA-MUC-1 antigen.
NEMOD Immuntherapie AG is a drug discovery company affiliated with publicly listed Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700, German Prime Standard) and dedicated to the development and commercialization of its proprietary PankoMab(TM) technology.
Andreas Hey, Chief Operating Officer, of NEMOD Immuntherapie AG, +49-30-941084-282